Top 10 Oncogenic Markers in Advanced NSCLC: What You Need to Know About Testing, Trials, and Novel Therapies

Target Audience
This educational program is directed toward the American Society of Clinical Oncology (ASCO) audience, including medical oncologists, pathologists, and pulmonologists interested in the treatment of advanced NSCLC. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and those involved in the treatment of patients with advanced NSCLC, are also invited to participate.

Program Overview
In this online, on-demand virtual symposium, an expert panel review updated strategies to improve the application and interpretation of testing in non–small cell lung cancer (NSCLC) to identify actionable alterations. Additionally, the latest data on the safety and efficacy of emerging targeted therapies is presented, followed by a panel discussion and interactive question-and-answer sessions to help integrate these emerging data into the personalized care of your patients with NSCLC.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Outline current and emerging molecular biomarkers that facilitate treatment personalization in NSCLC
Describe current and evolving testing strategies for biomarker detection in patients with NSCLC
Review recent clinical trial data and strategies for integrating current and recently approved targeted therapies into clinical practice for the treatment of patients with advanced NSCLC
Assess the implications of emerging targets, therapies, and strategies in the treatment of patients with advanced NSCLC